RT Journal Article
SR Electronic
T1 Longevity of SARS-CoV-2 Antibody in Health Care Workers: 6-Months Follow Up
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.25.21262632
DO 10.1101/2021.08.25.21262632
A1 Michael Brant-Zawadzki
A1 Deborah Fridman
A1 Philip A. Robinson
A1 Randy German
A1 Arell Shapiro
A1 Marcus Breit
A1 Stacy Wilton
A1 Elmira Burke
A1 Jason R. Bock
A1 Junko Hara
YR 2021
UL http://medrxiv.org/content/early/2021/08/26/2021.08.25.21262632.abstract
AB The prevalence and longevity of acquired immunity to coronavirus disease 2019 (COVID-19) in health care workers (HCWs) is of great interest, especially with the roll-out of vaccines for SARS-CoV-2. Determining such immunity may enhance knowledge about susceptibility of HCWs to COVID-19, frequency of vaccine administration, and degree of workplace risk, and may also support enactment of better workplace policies and procedures.The present study reports on 6-months follow-up serosurveillance to determine the longevity of SARS-CoV-2 antibodies in HCWs.Sub-sample (n=35) of the original serosurveillance in HCWs (n = 3,458) with baseline, 8-week, and 6-month blood sampling were analyzed. Information on job duties, location, COVID-19 symptoms, polymerase chain reaction test history, travel since January 2020, and household contacts with COVID-19 was collected.Of 35 subjects, 13 were seropositive at baseline and maintained positivity at 8-week follow-up, with 3 losing positivity at 6-month follow-up. Among 22 subjects who were seronegative at baseline and seropositive at 8-week follow-up, all but one maintained positivity at 6-month follow-up. There was no significant effect of all factors (e.g., age, gender, job duties) examined at the .05 level on seropositivity at 6-month follow-up. The observed antibody longevity was 7.0+/-0.6 months for seropositive subjects (n=13), and 4.5+/-0.8 months for those seronegative subjects (n=22), at baseline. The longest duration of seropositivity observed in this cohort was 7.9 months (236 days).With reported COVID-19-related symptoms up to 4.7 months prior to baseline blood sampling, possibly longer antibody presence is suggested. Similarly, seropositivity at 6-month follow-up further suggests greater antibody longevity than observed in this study.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Orange County Healthcare Agency and Hoag Hospital Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB approval was obtained for this study (Providence St. Joseph Health IRB # 2020000337).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data referred in this study will be available through figshre.com.